Hitching a quick ride on the M&A train, AstraZeneca wagers $100M cash on T cell engager - Endpoints News
7/5/2022 12:00:00 AM2 years 9 months ago
by Amber Tong
by Amber Tong
AstraZeneca has engineered a $1.27 billion deal to acquire a small biotech and its T cell engager — with an eye to shaking up the standards of care in multiple B cell malignancies. The deal to snap up TeneoTwo, which starts with $100 million upfront, marks th…
A renamed CRO with deep ties in the US and China has pulled in another round of capital. ClinChoice, formerly Fountain Medical Development, has completed a $150 million Series E funding round, using… [+530 chars]
full article...